Follicular Lymphoma | Tumor

Access to Therapies Through Clinical Trials ‘a Blessing’ for Lymphoma, Other Cancers

April 18th 2023, 7:00pm

Article

One patient was able to access a therapy for follicular lymphoma before it was approved by the FDA, which allowed him to help future patients through his experience.

FDA Approves Lunsumio to Treat Relapsed/Refractory Follicular Lymphoma

December 23rd 2022, 2:01pm

Article

Patients with relapsed/refractory follicular lymphoma — a group that traditionally has limited treatment options — now have a new bispecific antibody available.

Revlimid-Rituxan Combo May Offer Alternative to Chemotherapy for Lymphoma Subtype

August 22nd 2022, 1:09pm

Article

The combination treatment demonstrated survival and safety results similar to those of chemotherapy for patients with advanced, untreated follicular lymphoma.

FDA’s Approval of Breyanzi Gives Some Patients With Lymphoma a ‘Life-Saving Therapy', Says Expert

July 8th 2022, 7:00pm

Article

The FDA approval of Breyanzi, a novel CAR-T cell therapy, provides many patients with lymphoma a new treatment option that can be used earlier in the course of their disease, according to an expert.

FDA Grants Lunsumio Priority Review for Relapsed/Refractory Follicular Lymphoma

July 7th 2022, 3:00pm

Article

The priority review comes following positive clinical trial results, which may lead to a shift in the treatment paradigm for follicular lymphoma, according to an expert.

FDA Approves Kymriah for Relapsed/Refractory Follicular Lymphoma

May 31st 2022, 1:59pm

Article

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.

Experimental Lymphoma Drug Shows ‘Robust Clinical Activity,’ Researchers Say

February 25th 2022, 2:00pm

Article

Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.

Kymriah Shows ‘Huge Potential’ for Patients With Heavily Pretreated, Relapsed Follicular Lymphoma

January 24th 2022, 7:59pm

Article

Kymriah may represent a more effective option than currently available treatments for patients with heavily pretreated follicular lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021, 8:00pm

Article

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

FDA Will Review New Drug to Treat Non-Hodgkin Lymphoma

November 1st 2021, 9:00pm

Article

The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.